June 04, 2026 08:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea®, in Europe further strengthening the Company’s growing biosimilars portfolio and expanding its presence in ophthalmology. The launch reflects Teva’s strategy to build a leading biosimilars business in […]

June 04, 2026 04:00 ET  | Source: Royal Philips June 4, 2026 Seven-year collaboration puts WellSpan at the forefront of diagnostics and imaging in community health through a groundbreaking research and innovation strategy aimed at shaping the future of care delivery Amsterdam and YORK, Pa. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology,

June 03, 2026 16:05 ET  | Source: Iovance Biotherapeutics, Inc. First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering

June 03, 2026 07:00 ET  | Source: Dark Horse Consulting Group WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biologics, a wholly-owned subsidiary of Innovent Biologics and global contract development and manufacturing organization (CDMO) specializing

New collaboration delivers the POCUS Fundamentals Certificate to clinicians worldwide, creating a structured entry point for point-of-care ultrasound training. June 03, 2026 00:40 ET  | Source: Inteleos, Inc. ROCKVILLE, Md. and HYDERABAD, India, June 03, 2026 (GLOBE NEWSWIRE) — The Point-of-Care Ultrasound (POCUS) Certification Academy, part of Inteleos, is partnering with Medvarsity to expand global access to

June 02, 2026 14:43 ET  | Source: Alamar Biosciences, Inc. NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices  Workflow extends NULISA into longitudinal, decentralized, and population-scale research FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in

June 02, 2026 09:00 ET  | Source: Royal Philips June 2, 2026  Philips receives FDA 510(k) clearance for Elevate Plus for EPIQ Elite and Affiniti, delivering AI advancements in general imaging ultrasound AI-powered workflow automation helps clinicians acquire high-quality reproducible images faster and with greater confidence Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in

June 01, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8,

Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). June 01, 2026 16:05 ET  | Source: Resmed, Inc. SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered

June 01, 2026 02:00 ET  | Source: Curium PARIS, June 01, 2026 (GLOBE NEWSWIRE) — Curium, a global leader in nuclear medicine, today announced at the Choose France summit in Versailles, a major industrial investment program in France to the value of €32 million. This investment will strengthen its production capabilities for radiopharmaceuticals through the creation of

May 28, 2026 09:00 ET  | Source: Royal Philips May 28, 2026 For the first time, Disney stories and characters will be integrated into Philips Ambient Experience for MRI at medical facilities around the world to help create calmer, more comfortable patient experiences Amsterdam, the Netherlands and Burbank, Calif. – Royal Philips (NYSE: PHG, AEX: PHIA) and The Walt Disney Company (NYSE:

May 27, 2026 08:00 ET  | Source: Callio Therapeutics SEATTLE and SINGAPORE, May 27, 2026 (GLOBE NEWSWIRE) — Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced that it will present a trial-in-progress poster highlighting the Phase 1 trial design of CLIO-8221 at the 2026 American

May 26, 2026 21:18 ET  | Source: Junshi Biosciences SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“NEOTORCH”, NCT04158440) of the

May 26, 2026 09:34 ET  | Source: Cosmos Health Inc. CHICAGO, May 26, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its financial guidance for the 2026–2029 period. Cosmos Health enters this guidance period following its strongest financial performance in Company history — full year 2025

AGC Biologics to provide process development and GMP manufacturing for a novel therapy, leveraging its global microbial network across Germany and Japan. May 25, 2026 20:00 ET  | Source: AGC Biologics, Inc. HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) — AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a